Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MacroGenics (MGNX) PT Raised to $37 at Wedbush on MARGENZA Approval

December 17, 2020 12:40 PM EST

Wedbush analyst David Nierengarten raised the price target on MacroGenics (NASDAQ: MGNX) to $37.00 (from $32.00) while maintaining an Outperform rating after MARGENZA was approved in HER2+ mBC.

... More